casirivimab/imdevimab
experimental anti-COVID-19 drug developed by Regeneron
Facts
8 properties- Instance of
- experimental drug, combination drug[2]
- Inception
- 2020[6]
- Developer
- Regeneron Pharmaceuticals[3]
- Has part(s)
- casirivimab, imdevimab[4][5]
- Has parts
- casirivimab, imdevimab
- Name
- REGN-COV2[8]
- Subject has role
- antiviral drug[9]
🏷️ Also known as
en Ronapreve
en casirivimab/imdevimab
en REGN10933/REGN10987
en REGN-COV
en REGN-COV2
ar كاسيريفيماب/إيميفيماب
cs kasirivimab a imdevimab
cs kasirivimab/imdevimab
cs casirivimab/imdevimab
ja カシリビマブ・イムデビマブ
ja カシリビマブ/イムデビマブ
ja カシリビマブおよびイムデビマブ
ja カシリビマブ及びイムデビマブ
ja ロナプリーヴ
ja ロナプリーブ
pl REGN-COV2
pt Casirivimabe/imdevimabe
pt Casirivimab/imdevimab
th คาซิริวิแมบ/อิมดีวิแมบ
uk касиривімаб/імдевімаб
🔖 Identifiers · 6
- Image (Wikimedia Commons)
- REGN-COV2 binding SARS-CoV-2 spike protein.png ↗
- DrugBank ID
- DB15691
- Google Knowledge Graph ID
- /g/11kdlx2p0b
- MedlinePlus drug identifier
- a620063
- UK Parliament thesaurus ID
- 491691
- WikiProjectMed ID
- Casirivimab/imdevimab
🔗 Connections
Instance of 2
Developer 1
Medical condition treated 1
Subject has role 1
← Drug or therapy used for treatment 1
← Research intervention 1
Press Enter · cited answer in seconds
0 sources
Summary
casirivimab/imdevimab is an experimental drug[1].